Who makes YH12852 IR 0.1mg?

YH12852 IR 0.1mg is developed by Yuhan Corporation.

What development phase is YH12852 IR 0.1mg in?

YH12852 IR 0.1mg is in Phase 1.

Last reviewed 2026-04-20 · How we verify

YH12852 IR 0.1mg

Yuhan Corporation · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	YH12852 IR 0.1mg
Sponsor	Yuhan Corporation
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 1/2a Trial of YH12852 in Healthy Subjects and Patients With Functional Constipation (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

YH12852 IR 0.1mg CI brief — competitive landscape report
YH12852 IR 0.1mg updates RSS · CI watch RSS
Yuhan Corporation portfolio CI